- Y Diweddaraf sydd Ar Gael (Diwygiedig)
- Pwynt Penodol mewn Amser (31/12/2020)
- Gwreiddiol (a wnaed Fel)
Point in time view as at 31/12/2020.
The Human Medicines Regulations 2012, SCHEDULE 11 is up to date with all changes known to be in force on or before 18 August 2024. There are changes that may be brought into force at a future date. Changes that have been made appear in the content and are referenced with annotations.
Changes and effects yet to be applied by the editorial team are only applicable when viewing the latest version or prospective version of legislation. They are therefore not accessible when viewing legislation as at a specific point in time. To view the ‘Changes to Legislation’ information for this provision return to the latest version view using the options provided in the ‘What Version’ box above.
Regulations 58(5);59(7); 60(11);66(8); 68(12); 104(4);105(9); 108(8); 110(9);130(11); 133(8); and 137
1.—(1) This Part of this Schedule applies to—U.K.
(a)an application for the grant of a UK marketing authorisation, certificate of registration or traditional herbal registration;
(b)an application to renew a UK marketing authorisation, certificate of registration or traditional herbal registration; F1...
(c)a proposal to revoke, vary or suspend a UK marketing authorisation, certificate of registration or traditional herbal registration (including variation by the variation or removal of a condition to which a UK marketing authorisation or a certificate of registration is subject) other than a proposal to vary the authorisation, certificate or registration on the application of or by agreement with its holder [F2; and
(d)a proposal to decide that the orphan criteria are not met in relation to a medicinal product which is the subject of an application for the grant of a UK marketing authorisation.]
[F3(1A) Paragraphs 12 and 13 of this Part also apply to—
(a)an application for the grant of a parallel import licence;
(b)an application to renew a parallel import licence;
(c)a proposal to revoke, vary or suspend a parallel import licence (including variation by the variation or removal of a condition to which a parallel import licence is subject) other than a proposal to vary the licence on the application of or by agreement with its holder; and
(d)a refusal to vary a parallel import licence following an application for a variation by the holder.]
[F4(2) In relation to an application for a UKMA(NI) or THR(NI), this Part is subject to Part 4 of this Schedule.]
Textual Amendments
F1Word in Sch. 11 para. 1(1)(b) omitted (31.12.2020) by virtue of The Human Medicines (Amendment etc.) (EU Exit) Regulations 2019 (S.I. 2019/775), regs. 1, 63(2)(a)(i); 2020 c. 1, Sch. 5 para. 1(1)
F2Sch. 11 para. 1(1)(d) and word inserted (31.12.2020) by S.I. 2019/775, reg. 63(2)(a)(ii) (as substituted by The Human Medicines and Medical Devices (Amendment etc.) (EU Exit) Regulations 2019 (S.I. 2019/1385), reg. 1, Sch. 1 para. 7(2); 2020 c. 1, Sch. 5 para. 1(1))
F3Sch. 11 para. 1(1A) inserted (31.12.2020) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2019 (S.I. 2019/775), regs. 1, 63(2)(b); 2020 c. 1, Sch. 5 para. 1(1)
F4Sch. 11 para. 1(2) substituted (31.12.2020) by S.I. 2019/775, reg. 63(2)(c) (as substituted by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 46(a))
2.—(1) The licensing authority must consult the appropriate committee if the authority proposes on grounds relating to safety, quality or efficacy—U.K.
(a)to refuse to grant or renew a UK marketing authorisation or traditional herbal registration in response to the application; or
(b)to revoke, vary or suspend a UK marketing authorisation or traditional herbal registration.
(2) The licensing authority must consult the appropriate committee if the authority proposes on grounds relating to safety or quality—
(a)to refuse to grant or renew a certificate of registration in response to the application; or
(b)to revoke, vary or suspend a certificate of registration.
[F5(2A) The licensing authority must consult the appropriate committee if the authority proposes to decide that the orphan criteria are not met in relation to a medicinal product which is the subject of an application for the grant of a UK marketing authorisation.]
(3) This paragraph is subject to paragraphs 3 and 4 (exceptions to requirement to consult).
(4) In this Schedule “the appropriate committee” in relation to any function means whichever of the bodies listed in paragraph (5) the licensing authority considers to be the appropriate body to perform that function.
(5) Those bodies are—
(a)the Commission; and
(b)any expert committee appointed by the licensing authority.
Textual Amendments
F5Sch. 11 para. 2(2A) inserted (31.12.2020) by S.I. 2019/775, reg. 63(2A) (as inserted by The Human Medicines and Medical Devices (Amendment etc.) (EU Exit) Regulations 2019 (S.I. 2019/1385), reg. 1, Sch. 1 para. 7(3); 2020 c. 1, Sch. 5 para. 1(1))
3.—(1) Paragraph 2 does not apply to a proposal to refuse to grant or renew a UK marketing authorisation, certificate of registration or traditional herbal registration [F6, or to a proposal to decide that the orphan criteria are not met in relation to a medicinal product which is the subject of an application for the grant of a UK marketing authorisation,] if—U.K.
(a)the licensing authority has asked the applicant to supply information that the licensing authority thinks is relevant to enable the application to be determined [F7or the decision to be made]; and
(b)the information has not been supplied to the authority within the relevant period.
(2) The relevant period is—
(a)where the licensing authority has completed its initial full assessment of the application, the period of six months beginning with the date when the authority asked the applicant to supply the information mentioned in sub-paragraph (1); or
(b)where the licensing authority has completed its assessment of any supplemental information, the period of three months beginning with the date when the authority asked the applicant to supply the information mentioned in sub-paragraph (1).
(3) The licensing authority may extend the relevant period if—
(a)the applicant asks it to do so;
(b)the applicant provides the grounds for that request; and
(c)the licensing authority thinks that the grounds are exceptional.
Textual Amendments
F6Words in Sch. 11 para. 3(1) inserted (31.12.2020) by S.I. 2019/775, reg. 63(2B)(a) (as inserted by The Human Medicines and Medical Devices (Amendment etc.) (EU Exit) Regulations 2019 (S.I. 2019/1385), reg. 1, Sch. 1 para. 7(3); 2020 c. 1, Sch. 5 para. 1(1))
F7Words in Sch. 11 para. 3(1)(a) inserted (31.12.2020) by S.I. 2019/775, reg. 63(2B)(b) (as inserted by The Human Medicines and Medical Devices (Amendment etc.) (EU Exit) Regulations 2019 (S.I. 2019/1385), reg. 1, Sch. 1 para. 7(3); 2020 c. 1, Sch. 5 para. 1(1))
4.—(1) Paragraph 2 does not apply to a proposal to suspend a UK marketing authorisation, certificate of registration or traditional herbal registration if the licensing authority thinks that, in the interests of safety, it is necessary to suspend the authorisation, certificate or registration with immediate effect for not more than three months.U.K.
(2) In that event the licensing authority must report the suspension to the appropriate committee forthwith.
(3) Sub-paragraph (4) applies if, following a suspension to which this paragraph applies—
(a)the licensing authority thinks that the authorisation, certificate or registration should be further suspended, or varied or revoked; or
(b)the appropriate committee advises that the authorisation, certificate or registration should be further suspended, or varied or revoked.
(4) The provisions of this Part of this Schedule (including this paragraph) apply accordingly to the suspension, variation or revocation.
5.—(1) If the appropriate committee is consulted under paragraph 2(1) it may give a provisional opinion that on grounds relating to safety, quality or efficacy—U.K.
(a)it may be unable to advise the licensing authority to grant or renew the UK marketing authorisation or traditional herbal registration;
(b)it may be unable to advise the licensing authority to grant the authorisation or registration unless—
(i)it contains terms other than those in the application, or
(ii)it is granted subject to conditions; or
(c)it may have to advise the licensing authority to revoke, vary or suspend the authorisation or registration.
(2) If the Commission is consulted under paragraph 2(2), it may give a provisional opinion that, on grounds relating to safety or quality—
(a)it may be unable to advise the licensing authority to grant or renew the certificate of registration;
(b)it may be unable to advise the licensing authority to grant the certificate unless—
(i)it contains terms other than those in the application, or
(ii)it is granted subject to conditions; or
(c)it may have to advise the licensing authority to revoke, vary or suspend the certificate.
[F8(2A) If the appropriate committee is consulted under paragraph 2(2A), it may give a provisional opinion that it may be unable to advise the licensing authority to decide that the orphan criteria are met in relation to a medicinal product which is the subject of an application for the grant of a UK marketing authorisation.]
(3) The appropriate committee must notify the applicant for the grant or renewal [F9 , the applicant intending to demonstrate that the orphan criteria are met in relation to a medicinal product,] or (as the case may be) the holder of the authorisation, certificate or registration in writing of its provisional opinion.
Textual Amendments
F8Sch. 11 para. 5(2A) inserted (31.12.2020) by S.I. 2019/775, reg. 63(2C)(a) (as inserted by The Human Medicines and Medical Devices (Amendment etc.) (EU Exit) Regulations 2019 (S.I. 2019/1385), reg. 1, Sch. 1 para. 7(3); 2020 c. 1, Sch. 5 para. 1(1))
F9Words in Sch. 11 para. 5(3) inserted (31.12.2020) by S.I. 2019/775, reg. 63(2C)(b) (as inserted by The Human Medicines and Medical Devices (Amendment etc.) (EU Exit) Regulations 2019 (S.I. 2019/1385), reg. 1, Sch. 1 para. 7(3); 2020 c. 1, Sch. 5 para. 1(1))
6.—(1) An applicant or holder notified under paragraph 5 may, by notice in writing to the appropriate committee, request the opportunity to make written or oral representations to the appropriate committee.U.K.
(2) The applicant or holder must make the request within the period of 28 days beginning with the day on which the notification is given or such longer period as the licensing authority may allow.
7.—(1) If the applicant or holder requests the opportunity to make written representations, the applicant or holder must provide the appropriate committee with those representations and any documents on which the applicant or holder wishes to rely in support of them—U.K.
(a)before the end of the period of six months beginning with the date of the request; or
(b)before the end of such shorter period as the appropriate committee may specify in the notification under paragraph 5.
(2) The appropriate committee may at the request of the applicant or holder extend the period mentioned in sub-paragraph (1) up to a maximum of twelve months beginning with the date of the request under paragraph 6.
(3) The applicant or holder may submit additional representations or documents after the end of the period for doing so only with the permission of the appropriate committee.
(4) The appropriate committee must—
(a)take the representations made under this paragraph into account; and
(b)report its findings and advice to the licensing authority together with the reasons for that advice.
8.—(1) If the applicant or holder requests the opportunity to make oral representations, the applicant or holder must provide the appropriate committee with a written summary of those representations and any documents on which the applicant or holder wishes to rely in support of them—U.K.
(a)before the end of the period of six months beginning with the date of the request; or
(b)before the end of such shorter period as the appropriate committee may specify in the notification under paragraph 5.
(2) The appropriate committee may at the request of the applicant or holder extend the period mentioned in sub-paragraph (1) up to a maximum of twelve months beginning with the date of the request under paragraph 6.
(3) The applicant or holder may submit additional written representations or documents after the end of the period for doing so only with the permission of the appropriate committee.
(4) After receiving the summary and any other documents provided under this paragraph, the appropriate committee must arrange for the applicant or holder to make oral representations at a hearing before the committee.
(5) The appropriate committee must—
(a)take the representations made under this paragraph into account; and
(b)report its findings and advice to the licensing authority together with the reasons for that advice.
9.—(1) This paragraph applies if the applicant or holder—U.K.
(a)does not request the opportunity to make written or oral representations to the appropriate committee within the period mentioned in paragraph 6;
(b)requests the opportunity to make written representations, but fails to make those written representations within the period for doing so; or
(c)requests the opportunity to make oral representations, but—
(i)fails to provide a summary of those representations or the documents in support of them within the period for doing so, or
(ii)fails to make oral representations at a hearing before the appropriate committee.
(2) The appropriate committee must notify the licensing authority of that fact.
10.—(1) After receiving the appropriate committee's report under paragraph 7 or 8 or notification under paragraph 9 the licensing authority must—U.K.
(a)decide whether to grant or renew the UK marketing authorisation, certificate of registration or traditional herbal registration;
(b)decide whether to grant or renew the authorisation, certificate or registration in accordance with the application; F10...
(c)decide whether to proceed with its proposal to revoke, vary or suspend the authorisation, certificate or registration [F11; or
(d)decide whether to proceed with its proposal to decide that the orphan criteria are not met in relation to a medicinal product which is the subject of an application for the grant of a UK marketing authorisation,]
as the case may be.
(2) If the appropriate committee has given a report under paragraph 7 or 8, the licensing authority must take the report into account in making its decision.
(3) The licensing authority must notify the applicant or holder of—
(a)its decision; and
(b)any advice given to it by the appropriate committee and the reasons for that advice.
Textual Amendments
F10Word in Sch. 11 para. 10(1)(b) omitted (31.12.2020) by virtue of S.I. 2019/775, reg. 63(2D)(a) (as inserted by The Human Medicines and Medical Devices (Amendment etc.) (EU Exit) Regulations 2019 (S.I. 2019/1385), reg. 1, Sch. 1 para. 7(3); 2020 c. 1, Sch. 5 para. 1(1))
F11Sch. 11 para. 10(1)(d) and word inserted (31.12.2020) by S.I. 2019/775, reg. 63(2D)(b) (as inserted by The Human Medicines and Medical Devices (Amendment etc.) (EU Exit) Regulations 2019 (S.I. 2019/1385), reg. 1, Sch. 1 para. 7(3); 2020 c. 1, Sch. 5 para. 1(1))
11.—(1) A person to whom a notification is given under paragraph 10 may notify the licensing authority in writing that the person wishes the licensing authority to submit the decision to review upon oral representations.U.K.
(2) The person must give the notification within the period of 28 days beginning with the day on which the notification under paragraph 10 is given or such longer period as the licensing authority may allow.
(3) The review must be conducted in accordance with Schedule 5.
(4) This paragraph does not apply if—
(a)the person has not made any representations in accordance with paragraph 7 or 8; and
(b)the decision of the licensing authority is in accordance with the advice of the appropriate committee.
12.—(1) This paragraph applies if the appropriate committee has not been consulted under paragraph 2(1) because the licensing authority proposes on grounds not relating to safety, quality or efficacy—U.K.
(a)to refuse to grant or renew a UK marketing authorisation [F12, parallel import licence] or traditional herbal registration in response to the application;
(b)to grant or renew a UK marketing authorisation [F12, parallel import licence] or traditional herbal registration otherwise than in accordance with the application; or
(c)to revoke, vary or suspend a UK marketing authorisation [F12, parallel import licence] or traditional herbal registration.
(2) This paragraph also applies if, having been consulted under paragraph 2(1), the appropriate committee has not given a provisional opinion in the terms described in paragraph 5(1), and the licensing authority proposes—
(a)to determine the application for the UK marketing authorisation or traditional herbal registration in a way that differs from the appropriate committee's advice;
(b)to revoke, vary or suspend the authorisation or registration against such advice; or
(c)on grounds not relating to safety, quality or efficacy—
(i)to refuse to grant or renew the authorisation or registration,
(ii)to grant or renew the authorisation or registration otherwise than in accordance with the application, or
(iii)to revoke, vary or suspend the authorisation or registration.
(3) This paragraph also applies if the appropriate committee has not been consulted under paragraph 2(2) because the licensing authority proposes on grounds not relating to safety or quality—
(a)to refuse to grant or renew a certificate of registration in response to the application;
(b)to grant or renew a certificate of registration otherwise than in accordance with the application; or
(c)to revoke, vary or suspend a certificate of registration.
(4) This paragraph also applies if, having been consulted under paragraph 2(2), the appropriate committee has not given a provisional opinion in the terms described in paragraph 5(2), and the licensing authority proposes—
(a)to determine the application for the certificate of registration in a way that differs from the appropriate committee's advice;
(b)to revoke, vary or suspend the authorisation against such advice; or
(c)on grounds not relating to safety or quality—
(i)to refuse to grant or renew the certificate,
(ii)to grant or renew the certificate otherwise than in accordance with the application, or
(iii)to revoke, vary or suspend the certificate.
[F13(4A) This paragraph also applies if, having been consulted under paragraph 2(2A), the appropriate committee has not given a provisional opinion in the terms described in paragraph 5(2A) and the licensing authority proposes to decide, against that committee's advice, that the orphan criteria are not met in relation to a medicinal product which is the subject of an application for the grant of a UK marketing authorisation.]
(5) The licensing authority must notify the applicant for the grant or renewal or (as the case may be) the holder of the authorisation [F14, licence], certificate or registration in writing of its proposal.
(6) The notification must state—
(a)the reasons for the proposal; and
(b)any advice of the appropriate committee and any reasons it has given for that advice.
Textual Amendments
F12Words in Sch. 11 para. 12(1) inserted (31.12.2020) by S.I. 2019/775, reg. 63(3)(a) (as substituted by The Human Medicines and Medical Devices (Amendment etc.) (EU Exit) Regulations 2019 (S.I. 2019/1385), reg. 1, Sch. 1 para. 7(4); 2020 c. 1, Sch. 5 para. 1(1))
F13Sch. 11 para. 12(4A) inserted (31.12.2020) by S.I. 2019/775, reg. 63(3)(c) (as substituted by The Human Medicines and Medical Devices (Amendment etc.) (EU Exit) Regulations 2019 (S.I. 2019/1385), reg. 1, Sch. 1 para. 7(4); 2020 c. 1, Sch. 5 para. 1(1))
F14Word in Sch. 11 para. 12(5) inserted (31.12.2020) by S.I. 2019/775, reg. 63(3)(b) (as substituted by The Human Medicines and Medical Devices (Amendment etc.) (EU Exit) Regulations 2019 (S.I. 2019/1385), reg. 1, Sch. 1 para. 7(4); 2020 c. 1, Sch. 5 para. 1(1))
13.—(1) A person to whom a notification is given under paragraph 12 may—U.K.
(a)notify the licensing authority in writing that the person wishes the licensing authority to submit the proposal to review upon oral representations, or
(b)make representations in writing to the licensing authority with respect to the proposal.
(2) The person must give the notification or make the representations within the period of 28 days beginning with the day on which the notification is given or such longer period as the licensing authority may allow.
(3) A review in accordance with sub-paragraph (1)(a) must be conducted in accordance with Schedule 5.
(4) If the person makes written representations in accordance with sub-paragraph (1)(b) the licensing authority must take them into account before determining the matter.
Textual Amendments
13A. This Part applies to a proposed decision by the licensing authority—
(a)to refuse to agree a paediatric investigation plan (including a waiver or deferral proposed to be included in that plan), or to agree such a plan otherwise than in accordance with the request for agreement;
(b)to refuse to agree a modification to a paediatric investigation plan (including a waiver or deferral which is, or is proposed to be, included in that plan), or to agree such a modification otherwise than in accordance with the request for the modification;
(c)to impose, revoke or refuse to grant a waiver of the obligation under regulation 50A(3) to provide to the licensing authority the results of all studies performed, and details of all information collected, in compliance with an agreed paediatric investigation plan; or
(d)to revoke a waiver which was agreed as part of an agreed paediatric investigation plan.
13B.—(1) If the licensing authority proposes to make a decision to which this Part applies, the licensing authority must notify the person to whom the proposed decision would be addressed (“the applicant”).
(2) The applicant may, by notice in writing to the licensing authority, request the opportunity to make written or oral representations to the appropriate committee.
(3) The applicant must make the request before the end of the period of 28 days beginning with the day on which the notification is given or such longer period as the licensing authority may allow.
(4) The licensing authority must inform the appropriate committee of the applicant's request.
13C.—(1) If the applicant requests the opportunity to make written representations, the applicant must provide the appropriate committee with those representations and any documents on which the applicant wishes to rely in support of them—
(a)before the end of the period of 28 days beginning with the date of the request; or
(b)before the end of such shorter period as the licensing authority may specify in the notification under paragraph 13B.
(2) The appropriate committee may at the request of the applicant extend the period mentioned in sub-paragraph (1) up to a maximum of 56 days beginning with the date of the request under paragraph 13B.
(3) The applicant may submit additional representations or documents after the end of the period for doing so only with the permission of the appropriate committee.
(4) The appropriate committee must—
(a)take the representations made under this paragraph into account; and
(b)report its findings and advice to the licensing authority together with the reasons for that advice.
13D.—(1) If the applicant requests the opportunity to make oral representations, the applicant must provide the appropriate committee with a written summary of those representations and any documents on which the applicant wishes to rely in support of them—
(a)before the end of the period of 28 days beginning with the date of the request; or
(b)before the end of such shorter period as the licensing authority may specify in the notification under paragraph 13B.
(2) The appropriate committee may, at the request of the applicant, extend the period mentioned in sub-paragraph (1) up to a maximum of 56 days beginning with the date of the request under paragraph 13B.
(3) The applicant may submit additional representations or documents after the end of the period for doing so only with the permission of the appropriate committee.
(4) After receiving the summary and any other documents provided under this paragraph, the appropriate committee must arrange for the applicant to make oral representations at a hearing before the committee.
(5) The appropriate committee must—
(a)take the representations made under this paragraph into account; and
(b)report its findings and advice to the licensing authority together with the reasons for that advice.
13E.—(1) This paragraph applies if the applicant—
(a)requests the opportunity to make written representations, but fails to make those representations within the period for doing so; or
(b)requests the opportunity to make oral representations, but—
(i)fails to provide a summary of those representations or the documents in support of them within the period for doing so, or
(ii)fails to make oral representations at a hearing before the appropriate committee.
(2) The appropriate committee must notify the licensing authority of that fact.
13F.—(1) The licensing authority must decide whether to proceed with its proposed decision—
(a)if the applicant requested the opportunity to make written or oral representations, after receiving the appropriate committee's report under paragraph 13C or 13D or notification under paragraph 13E; or
(b)if the applicant did not request the opportunity to make written or oral representations, after the expiry of the period of time for notifying a request for that opportunity.
(2) If the appropriate committee gives a report under paragraph 13C or 13D, the licensing authority must take that into account in making its decision.
(3) The licensing authority must notify the applicant of—
(a)its decision; and
(b)any advice given to it by the appropriate committee and the reasons for that advice.
13G.—(1) This paragraph applies if the licensing authority notifies the applicant of its decision under paragraph 13F.
(2) The applicant may notify the licensing authority in writing that the applicant wishes the licensing authority to submit the decision to review upon oral representations.
(3) The applicant must give the notification before the end of the period of 28 days beginning with the day on which the notification is given to the applicant under paragraph 13F or such longer period as the licensing authority may allow.
(4) The review must be conducted in accordance with Schedule 5.
(5) This paragraph does not apply if the applicant has not made any representations in accordance with paragraph 13C or 13D.]
14. This Part applies—U.K.
(a)to an application (a “Type II variation application”) to vary a UK marketing authorisation if the variation is a major variation of Type II within the meaning of Article 2(3) of Commission Regulation (EC) No 1234/2008 of 24 November 2008 concerning the examination of variations to the terms of marketing authorisations for medicinal products for human use and veterinary medicinal products M1 [F16or paragraph 1 of Schedule 10A]; and
(b)to an application to vary a traditional herbal registration that is—
(i)a complex variation application, or
(ii)a new excipient variation application.
Textual Amendments
F16Words in Sch. 11 para. 14(a) inserted (31.12.2020) by S.I. 2019/775, reg. 63(4) (as substituted by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 46(b))
Marginal Citations
M1OJ No L 334, 12.12.2008, p.7.
15.—(1) In paragraph 14(b)(i) “complex variation application” means an application by the holder of the registration to vary it so that one or more of the following changes can be made to the product to which it relates—U.K.
(a)a change in the product's active ingredients by the addition of an active ingredient from a new source;
(b)a change in the product's excipients by the addition of a TSE risk excipient from a new source; or
(c)a change by the addition of a vitamin or mineral from a new source, where no European Pharmacopoeia certificate of suitability for the vitamin or mineral is submitted with the application.
(2) For the purpose of sub-paragraph (1), an ingredient, vitamin or mineral is “from a new source” if its manufacturer as named in the application has not been named as its manufacturer in a [F17UK] marketing authorisation or traditional herbal registration granted for a medicinal product including the ingredient, vitamin or mineral.
(3) For the purpose of sub-paragraph (1), an excipient is a “TSE risk excipient from a new source” if—
(a)it has been manufactured from raw materials of ruminant origin or such raw materials have been used in its manufacture; and
(b)its manufacturer as named in the application has not been named as its manufacturer in a [F18UK] marketing authorisation or traditional herbal registration granted for a medicinal product that includes the excipient.
Textual Amendments
F17Word in Sch. 11 para. 15(2) inserted (31.12.2020) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2019 (S.I. 2019/775), regs. 1, 63(5); 2020 c. 1, Sch. 5 para. 1(1)
F18Word in Sch. 11 para. 15(3)(b) inserted (31.12.2020) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2019 (S.I. 2019/775), regs. 1, 63(5); 2020 c. 1, Sch. 5 para. 1(1)
16.—(1) In paragraph 14(b)(ii) “new excipient variation application” means an application (other than a complex variation application) by the holder of the registration to vary it so that the formulation of the medicinal product to which it relates can be changed by the addition of a new excipient.U.K.
(2) For the purpose of sub-paragraph (1) “new excipient” means, subject to paragraphs (3) and (4), an ingredient of a medicinal product that is not an active ingredient and that has not been included in a medicinal product—
(a)intended to be administered by the same route as the product to which the application relates; and
(b)for which a [F19UK] marketing authorisation (other than a product licence of right) or traditional herbal registration has been granted.
(3) In the application of sub-paragraph (1) to a medicinal product intended to be administered orally, the reference to a new excipient does not include any ingredient specified in an enactment as an approved ingredient or additive in food or in a food product.
(4) In the application of sub-paragraph (1) to a medicinal product intended for external use only, the reference to a new excipient does not include any ingredient specified in an enactment as an approved ingredient or additive in a cosmetic product.
(5) In this paragraph “enactment” includes an enactment comprised in subordinate legislation F20....
Textual Amendments
F19Word in Sch. 11 para. 16(2)(b) inserted (31.12.2020) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2019 (S.I. 2019/775), regs. 1, 63(6)(a); 2020 c. 1, Sch. 5 para. 1(1)
F20Words in Sch. 11 para. 16(5) omitted (31.12.2020) by virtue of The Human Medicines (Amendment etc.) (EU Exit) Regulations 2019 (S.I. 2019/775), regs. 1, 63(6)(b); 2020 c. 1, Sch. 5 para. 1(1)
[F2117. In relation to an application for a UKMA(NI) or THR(NI), this Part is subject to Part 4 of this Schedule.]U.K.
Textual Amendments
F21Sch. 11 para. 17 substituted (31.12.2020) by S.I. 2019/775, reg. 63(7) (as substituted by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 46(c))
18.—(1) This paragraph applies if the licensing authority notifies the applicant for a variation to which this Part applies that it has decided, on grounds relating to safety, quality or efficacy—U.K.
(a)to refuse to grant the application, or
(b)to grant it otherwise than in accordance with the application.
(2) The applicant may by notice in writing to the licensing authority request the opportunity to make written or oral representations to the appropriate committee.
(3) The applicant must make the request within the period of 28 days beginning with the day on which the notification is given or such longer period as the licensing authority may allow.
(4) The licensing authority must inform the appropriate committee of the applicant or holder's request.
19.—(1) If the applicant requests the opportunity to make written representations, the applicant must provide the appropriate committee with those representations and any documents on which the applicant wishes to rely in support of them—U.K.
(a)before the end of the period of six months beginning with the date of the request; or
(b)before the end of such shorter period as the licensing authority may specify in the notification under paragraph 18.
(2) The appropriate committee may, at the request of the applicant, extend the period mentioned in sub-paragraph (1) up to a maximum of twelve months beginning with the date of the request under paragraph 18.
(3) The applicant may submit additional representations or documents after the end of the period for doing so only with the permission of the appropriate committee.
(4) The appropriate committee must—
(a)take the representations made under this paragraph into account; and
(b)report its findings and advice to the licensing authority together with the reasons for that advice.
20.—(1) If the applicant requests the opportunity to make oral representations, the applicant must provide the appropriate committee with a written summary of those representations and any documents on which the applicant wishes to rely in support of them—U.K.
(a)before the end of the period of six months beginning with the date of the request; or
(b)before the end of such shorter period as the licensing authority may specify in the notification under paragraph 18.
(2) The appropriate committee may, at the request of the applicant, extend the period mentioned in sub-paragraph (1) up to a maximum of twelve months beginning with the date of the request under paragraph 18.
(3) The applicant may submit additional written representations or documents after the end of the period for doing so only with the permission of the appropriate committee.
(4) After receiving the summary and any other documents provided under this paragraph, the appropriate committee must arrange for the applicant to make oral representations at a hearing before the committee.
(5) The appropriate committee must—
(a)take the representations made under this paragraph into account; and
(b)report its findings and advice to the licensing authority together with the reasons for that advice.
21.—(1) This paragraph applies if the applicant—U.K.
(a)requests the opportunity to make written representations, but fails to make those written representations within the period for doing so; or
(b)requests the opportunity to make oral representations, but—
(i)fails to provide a summary of those representations or the documents in support of them within the period for doing so, or
(ii)fails to make oral representations at a hearing before the appropriate committee.
(2) The appropriate committee must notify the licensing authority of that fact.
22.—(1) After receiving the appropriate committee's report under paragraph 19 or 20 or notification under paragraph 21 the licensing authority must confirm or alter its decision.U.K.
(2) If the appropriate committee gives a report under paragraph 19 or 20, the licensing authority must take that into account in making its decision.
(3) The licensing authority must notify the applicant or holder of—
(a)its decision; and
(b)any advice given to it by the appropriate committee and the reasons for that advice.
23.—(1) This paragraph applies if the licensing authority notifies the applicant of its decision under paragraph 22—U.K.
(a)to refuse the application; or
(b)to grant it otherwise than in accordance with the application.
(2) The applicant may notify the licensing authority in writing that the person wishes the licensing authority to submit the decision to review upon oral representations.
(3) The applicant must give the notification within the period of 28 days beginning with the day on which the notification is given or such longer period as the licensing authority may allow.
(4) The review must be conducted in accordance with Schedule 5.
(5) This paragraph does not apply if the person has not made any representations in accordance with paragraph 19 or 20.
Textual Amendments
F22Words in Sch. 11 Pt. 3 heading substituted (31.12.2020) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2019 (S.I. 2019/775), regs. 1, 63(8)(a); 2020 c. 1, Sch. 5 para. 1(1)
24.—(1) This Part applies if the licensing authority proposes to refer an application for a traditional herbal registration to the [F23appropriate committee in accordance with regulation 130A(1)].U.K.
[F24(2) In relation to an application for a UKMA(NI) or THR(NI), this Part is subject to Part 4 of this Schedule.]
Textual Amendments
F23Words in Sch. 11 para. 24(1) substituted (31.12.2020) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2019 (S.I. 2019/775), regs. 1, 63(8)(b)(i); 2020 c. 1, Sch. 5 para. 1(1)
F24Sch. 11 para. 24(2) substituted (31.12.2020) by S.I. 2019/775, reg. 63(8)(b)(ii) (as substituted by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 46(d))
25.—(1) The licensing authority must notify the applicant of the authority's proposal.U.K.
(2) The applicant may by notice in writing to the licensing authority request the opportunity to make written or oral representations to the appropriate committee.
(3) The applicant must make the request within the period of 28 days beginning with the day on which the notification is given or such longer period as the licensing authority may allow.
(4) The licensing authority must inform the appropriate committee of the applicant or holder's request.
26.—(1) If the applicant requests the opportunity to make written representations, the applicant must provide the appropriate committee with those representations and any documents on which the applicant wishes to rely in support of them—U.K.
(a)before the end of the period of six months beginning with the date of the request; or
(b)before the end of such shorter period as the licensing authority may specify in the notification under paragraph 25.
(2) The appropriate committee may, at the request of the applicant, extend the period mentioned in sub-paragraph (1) up to a maximum of twelve months beginning with the date of the request under paragraph 25.
(3) The applicant may submit additional representations or documents after the end of the period for doing so only with the permission of the appropriate committee.
(4) The appropriate committee must—
(a)take the representations made under this paragraph into account; and
(b)report its findings and advice to the licensing authority together with the reasons for that advice.
27.—(1) If the applicant requests the opportunity to make oral representations, the applicant must provide the appropriate committee with a written summary of those representations and any documents on which the applicant wishes to rely in support of them—U.K.
(a)before the end of the period of six months beginning with the date of the request; or
(b)before the end of such shorter period as the licensing authority may specify in the notification under paragraph 25.
(2) The appropriate committee may, at the request of the applicant, extend the period mentioned in sub-paragraph (1) up to a maximum of twelve months beginning with the date of the request under paragraph 24.
(3) The applicant may submit additional written representations or documents after the end of the period for doing so only with the permission of the appropriate committee.
(4) After receiving the summary and any other documents provided under this paragraph, the appropriate committee must arrange for the applicant to make oral representations at a hearing before the appropriate committee.
(5) The appropriate committee must—
(a)take the representations made under this paragraph into account; and
(b)report its findings and advice to the licensing authority together with the reasons for that advice.
28.—(1) This paragraph applies if the applicant—U.K.
(a)requests the opportunity to make written representations, but fails to make those written representations within the period for doing so; or
(b)requests the opportunity to make oral representations, but—
(i)fails to provide a summary of those representations or the documents in support of them within the period for doing so, or
(ii)fails to make oral representations at a hearing before the appropriate committee.
(2) The appropriate committee must notify the licensing authority of that fact.
29.—(1) After receiving the appropriate committee's report under paragraph 26 or 27 or notification under paragraph 28 the licensing authority must decide whether to [F25grant or refuse the application].U.K.
(2) If the appropriate committee gives a report under paragraph 26 or 27, the licensing authority must take that into account in making its decision.
(3) The licensing authority must notify the applicant or holder of—
(a)its decision; and
(b)any advice given to it by the appropriate committee and the reasons for that advice.
Textual Amendments
F25Words in Sch. 11 para. 29(1) substituted (31.12.2020) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2019 (S.I. 2019/775), regs. 1, 63(8)(c); 2020 c. 1, Sch. 5 para. 1(1)
30.—(1) This paragraph applies if the licensing authority notifies the applicant of its decision under paragraph 29 to refer the applicant to the Committee on Herbal Medicinal Products as proposed.U.K.
(2) The applicant may notify the licensing authority in writing that the person wishes the licensing authority to submit the decision to review upon oral representations.
(3) The applicant must give the notification within the period of 28 days beginning with the day on which the licensing authority's notification is given or such longer period as the licensing authority may allow.
(4) The review must be conducted in accordance with Schedule 5.
(5) This paragraph does not apply if the person has not made any representations in accordance with paragraph 26 or 27.
F2631. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .U.K.
Textual Amendments
F26Sch. 11 para. 31 omitted (31.12.2020) by virtue of S.I. 2019/775, reg. 63(9) (as substituted by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 46(e))
32. This Schedule does not apply to an application for the grant of a UK marketing authorisation, certificate of registration or traditional herbal registration if the application has been submitted to the licensing authority in accordance with Article 28 of the 2001 Directive.U.K.
33. This Schedule ceases to apply if at any time the matter in question is referred to the Committee for Medicinal Products for Human Use or the Committee for Herbal Medicinal Products under Article 30 or 31 of the 2001 Directive for the application of the procedure laid down in Articles 32 to 34 of that Directive.U.K.
F2734. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .U.K.
Textual Amendments
F27Sch. 11 para. 34 omitted (31.12.2020) by virtue of S.I. 2019/775, reg. 63(9) (as substituted by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 46(e))
F2835. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .U.K.
Textual Amendments
F28Sch. 11 para. 35 omitted (31.12.2020) by virtue of S.I. 2019/775, reg. 63(9) (as substituted by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 46(e))
36. This Schedule does not apply if the application or proposal relates to the renewal, revocation, suspension or variation of a UK marketing authorisation that—U.K.
(a)was granted in accordance with the provisions of Chapter 4 of Title III to the 2001 Directive (mutual recognition procedure and decentralised procedure);
(b)was granted before 1st January 1995 by member States in accordance with Article 4 of Council Directive 87/22/EEC of 22 December 1986 on the approximation of national measures relating to the placing on the market of high-technology medicinal products, particularly those derived from biotechnology M2; or
(c)was subject to the procedure laid down in Articles 32 to 34 of the 2001 Directive following a referral under Article 30 or 31 of that Directive, unless the procedure was limited to certain specific parts of the authorisation.
Marginal Citations
M2OJ No L 15, 17.1.1987. p.38.
F2937. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .U.K.
Textual Amendments
F29Sch. 11 para. 37 omitted (31.12.2020) by virtue of S.I. 2019/775, reg. 63(9) (as substituted by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 46(e))
F3038. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .U.K.
Textual Amendments
F30Sch. 11 para. 38 omitted (31.12.2020) by virtue of S.I. 2019/775, reg. 63(9) (as substituted by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 46(e))
39. This Schedule does not apply if—U.K.
(a)the licensing authority refuse to grant an application for a traditional herbal registration;
(b)the application was referred to the Committee for Herbal Medicinal Products in accordance with Article 16c(4) of the 2001 Directive; and
(c)the Committee for Herbal Medicinal Products did not support the grant of the application.
The Whole Instrument you have selected contains over 200 provisions and might take some time to download. You may also experience some issues with your browser, such as an alert box that a script is taking a long time to run.
Would you like to continue?
The Whole Instrument you have selected contains over 200 provisions and might take some time to download.
Would you like to continue?
Yr Offeryn Cyfan you have selected contains over 200 provisions and might take some time to download. You may also experience some issues with your browser, such as an alert box that a script is taking a long time to run.
Would you like to continue?
Yr Offeryn Cyfan heb Atodlenni you have selected contains over 200 provisions and might take some time to download. You may also experience some issues with your browser, such as an alert box that a script is taking a long time to run.
Would you like to continue?
Y Rhestrau you have selected contains over 200 provisions and might take some time to download. You may also experience some issues with your browser, such as an alert box that a script is taking a long time to run.
Would you like to continue?
Y Diweddaraf sydd Ar Gael (diwygiedig):Y fersiwn ddiweddaraf sydd ar gael o’r ddeddfwriaeth yn cynnwys newidiadau a wnaed gan ddeddfwriaeth ddilynol ac wedi eu gweithredu gan ein tîm golygyddol. Gellir gweld y newidiadau nad ydym wedi eu gweithredu i’r testun eto yn yr ardal ‘Newidiadau i Ddeddfwriaeth’.
Gwreiddiol (Fel y’i Deddfwyd neu y’i Gwnaed): Mae'r wreiddiol fersiwn y ddeddfwriaeth fel ag yr oedd pan gafodd ei deddfu neu eu gwneud. Ni wnaed unrhyw newidiadau i’r testun.
Pwynt Penodol mewn Amser: This becomes available after navigating to view revised legislation as it stood at a certain point in time via Advanced Features > Show Timeline of Changes or via a point in time advanced search.
Rhychwant ddaearyddol: Indicates the geographical area that this provision applies to. For further information see ‘Frequently Asked Questions’.
Dangos Llinell Amser Newidiadau: See how this legislation has or could change over time. Turning this feature on will show extra navigation options to go to these specific points in time. Return to the latest available version by using the controls above in the What Version box.
Mae Memoranda Esboniadol yn nodi datganiad byr o ddiben Offeryn Statudol ac yn rhoi gwybodaeth am ei amcan polisi a goblygiadau polisi. Maent yn ceisio gwneud yr Offeryn Statudol yn hygyrch i ddarllenwyr nad oes ganddynt gymhwyster cyfreithiol, ac maent yn cyd-fynd ag unrhyw Offeryn Statudol neu Offeryn Statudol Drafft a gyflwynwyd ger bron y Senedd o Fehefin 2004 ymlaen.
Gallwch wneud defnydd o ddogfennau atodol hanfodol a gwybodaeth ar gyfer yr eitem ddeddfwriaeth o’r tab hwn. Yn ddibynnol ar yr eitem ddeddfwriaeth sydd i’w gweld, gallai hyn gynnwys:
Impact Assessments generally accompany all UK Government interventions of a regulatory nature that affect the private sector, civil society organisations and public services. They apply regardless of whether the regulation originates from a domestic or international source and can accompany primary (Acts etc) and secondary legislation (SIs). An Impact Assessment allows those with an interest in the policy area to understand:
This timeline shows the different points in time where a change occurred. The dates will coincide with the earliest date on which the change (e.g an insertion, a repeal or a substitution) that was applied came into force. The first date in the timeline will usually be the earliest date when the provision came into force. In some cases the first date is 01/02/1991 (or for Northern Ireland legislation 01/01/2006). This date is our basedate. No versions before this date are available. For further information see the Editorial Practice Guide and Glossary under Help.
Defnyddiwch y ddewislen hon i agor dogfennau hanfodol sy’n cyd-fynd â’r ddeddfwriaeth a gwybodaeth am yr eitem hon o ddeddfwriaeth. Gan ddibynnu ar yr eitem o ddeddfwriaeth sy’n cael ei gweld gall hyn gynnwys:
liciwch ‘Gweld Mwy’ neu ddewis ‘Rhagor o Adnoddau’ am wybodaeth ychwanegol gan gynnwys